ecteinascidin 743 has been researched along with Lymph Node Metastasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M | 1 |
| Brain, E; Jimeno, J; Misset, JL; Riofrio, M; Spielmann, M; Taamma, A; Turpin, F; Yovine, A; Zelek, L | 1 |
1 trial(s) available for ecteinascidin 743 and Lymph Node Metastasis
| Article | Year |
|---|---|
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Isoquinolines; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Tetrahydroisoquinolines; Trabectedin | 2006 |
1 other study(ies) available for ecteinascidin 743 and Lymph Node Metastasis
| Article | Year |
|---|---|
Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
Topics: Adenocarcinoma, Clear Cell; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dioxoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Tetrahydroisoquinolines; Trabectedin | 2013 |